Journal article
Elevated serum monoclonal and polyclonal free light chains and Interferon inducible protein-10 (IP-10) predicts inferior prognosis in untreated diffuse large B-cell lymphoma
American journal of hematology, Vol.89(4), pp.417-422
04/2014
DOI: 10.1002/ajh.23658
PMCID: PMC4211415
PMID: 24382707
Abstract
The detection of serum free light (FLC) is useful in the diagnosis of several hematological diseases. The role and biological relevance of monoclonal or polyclonal FLC elevations in predicting long-term outcome in diffuse large B-cell lymphoma (DLBCL) is unknown. We determined the relationship of the type of FLC elevations to outcome, tumor genotype, and pattern of serum cytokine elevations in 276 patients with untreated DLBCL. Elevated FLC was an adverse prognostic factor through 6 years of follow-up (monoclonal, EFS HR = 3.56, 95% CI: 1.88-6.76, p<0.0001; polyclonal, EFS HR = 2.56, 95% CI: 1.50-4.38, p=0.0006). 73% of DLBCL tumors with monoclonal FLC elevations were activated B-cell type (ABC) vs. 33% from patients with normal FLC. Only ABC-DLBCL lines secreted kappa FLC in vitro and this secretion could be inhibited by the NF-κB inhibitor bortezomib. Patients with monoclonal FLC had significantly (all p<0.001) elevated serum levels of IL-12, sIL-2Rα, IL-1R, and IP-10. Patients with polyclonal elevations of FLC had higher levels of IL-6 (p=0.033), IL-8 (p=0.025), sIL2Rα (p=0.011), and IL-1R1 (p=0.041). The combination of elevated FLC and a CXC superfamily chemokine IP-10 predicted a particularly inferior outcome characterized by late relapse. These elevated abnormal FLC and cytokines are potentially useful biomarkers for prognosis and selecting agents for untreated DLBCL.
Details
- Title: Subtitle
- Elevated serum monoclonal and polyclonal free light chains and Interferon inducible protein-10 (IP-10) predicts inferior prognosis in untreated diffuse large B-cell lymphoma
- Creators
- Thomas E Witzig - Division of Hematology, Mayo Clinic, Rochester MNMatthew J Maurer - Department of Health Sciences Research, Mayo Clinic, Rochester, MNMary J Stenson - Division of Hematology, Mayo Clinic, Rochester MNCristine Allmer - Department of Health Sciences Research, Mayo Clinic, Rochester, MNWilliam Macon - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MNBrian Link - University of Iowa College of Medicine, Iowa City, IAJerry A Katzmann - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MNMamta Gupta - Division of Hematology, Mayo Clinic, Rochester MN
- Resource Type
- Journal article
- Publication Details
- American journal of hematology, Vol.89(4), pp.417-422
- DOI
- 10.1002/ajh.23658
- PMID
- 24382707
- PMCID
- PMC4211415
- ISSN
- 0361-8609
- eISSN
- 1096-8652
- Language
- English
- Date published
- 04/2014
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094357202771
Metrics
22 Record Views